Having a stimulating effect. An agonist drug, sometimes known as an activator, is one that binds to a sensory nerve cell (receptor) and triggers or increases a particular activity in that cell.
(1) A muscle which contracts and causes a movement. Contraction of an agonist is complemented by relaxation of its antagonist (see below).
(2) A drug that acts through receptors on the surface of the cell or within the cell and provokes a biological response. As the body contains natural agonists that combine with cell receptors, any ‘occupation’ of these cell receptors by drug molecules will have a pharmacological e?ect on the individual. The intensity of that pharmacological e?ect is believed to be directly proportional to the number of receptors on the cell that combine with the drug molecule. For example, the natural agonist noradrenaline contracts the smooth muscle of blood vessels; the drug agonist phenylnephrine has a similar e?ect.
Antagonists are drugs which will combine with the receptor site to prevent another agent from producing its greatest e?ect. If the drug has no e?cacy of its own, but simply prevents the agonist from acting at the receptor site, it is called a full antagonist. A partial antagonist is a drug that provokes some activity at the receptor site. An example of an antagonist is prazosin, which acts against the natural agonist noradrenaline at the receptor site of the cells of blood-vessel muscle and prevents the vascular muscle from contracting.
n. 1. (prime mover) a muscle whose active contraction causes movement of a part of the body. Contraction of an agonist is associated with relaxation of its *antagonist. 2. a drug or other substance that acts at a cell-receptor site to produce an effect that is the same as, or similar to, that of the body’s normal chemical messenger. *Sympathomimetic drugs (alpha agonists and beta agonists) are examples.
a group of drugs used in the treatment of type 2 diabetes. They mimic the actions of *glucagon-like peptide-1 in regulating the rise in blood glucose levels after eating and they also enhance satiety (see incretin). As these drugs respond to a falling blood glucose level there is a reduced tendency to *hypoglycaemia compared with *sulphonylurea drugs and insulin therapy itself. They are given by subcutaneous injection and three of them are licensed for use in the UK: exenatide (Byetta; twice daily dosing), liraglutide (Victoza; once daily dosing), and lixisenatide (Lyxumia; once daily dosing).... glp-1 receptor agonists